Ironwood Pharmaceuticals
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
公司地址 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
電話號碼 +1 617 621-7722
傳真號碼 +1 617 494-0480
公司網頁 https://www.ironwoodpharma.com
員工數量 253
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Tammi L. Gaskins Senior Vice President and Chief Commercial Officer -- 28/04/2025
Mr. Thomas A. McCourt Director, President and Chief Executive Officer 美元 867.57K 26/02/2026
Mr. Gregory S. Martini Senior Vice President and Chief Financial Officer -- 26/02/2026
Dr. Michael Shetzline, M.D.,PhD Senior Vice President, Chief Medical Officer and Head of Research and Drug Development 美元 557.57K 28/04/2025
Mr. John Minardo Senior Vice President, Chief Legal Officer and Secretary 美元 531.75K 28/04/2025
Mr. Ronald Silver, C.P.A. Principal Accounting Officer, Senior Vice President and Corporate Controller -- 26/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Alexander J. Denner, PhD Independent Director 26/02/2026
Mr. Jay P. Shepard Independent Director 26/02/2026
Dr. Mark G. Currie,PhD Independent Director 26/02/2026
Mr. Thomas A. McCourt Director, President and Chief Executive Officer 26/02/2026
Ms. Julie H. McHugh Chairman of the Board 26/02/2026
Ms. Catherine Moukheibir Independent Director 26/02/2026
Mr. Jon R. Duane Independent Director 26/02/2026
Ms. Marla L. Kessler Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:28)
代號 名稱 佔比% ▼ 持有日期
FLQSFranklin US Small Cap Mltfctr Idx ETF0.004%28/02/2026
ACSGAmerican Century Small Cp Gr Insgts ETF0.001%28/02/2026
FEACFidelity Enhanced U.S. All-Cap Eq ETF0.001%27/02/2026
PBSMInvesco PureBeta MSCI USA Small Cap ETF0.0004%31/05/2023
HDGProShares Hedge Replication0.0001%27/02/2026
AVTMAvantis Total Equity Markets ETF0.00004%28/02/2026
AOMiShares Core 40/60 Moderate Allc ETF<0.000001%27/02/2026
BBPVirtus LifeSci Biotech Products ETF<0.000001%16/06/2025
CALFPacer US Small Cap Cash Cows 100 ETF<0.000001%27/02/2026
EBITHarbor AlphaEdge Small Cap Earners ETF<0.000001%04/02/2026
EWSCInvesco S&P SmallCap 600® Equal Wt ETF<0.000001%20/03/2023
FHLCFidelity MSCI Health Care ETF<0.000001%03/06/2025
GSSCGoldman Sachs ActiveBeta® US SmCp Eq ETF<0.000001%30/06/2025
IJRiShares Core S&P Small-Cap ETF<0.000001%28/02/2026
IJSiShares S&P Small-Cap 600 Value ETF<0.000001%28/02/2026
IJTiShares S&P Small-Cap 600 Growth ETF<0.000001%28/02/2026
ISCBiShares Morningstar Small-Cap ETF<0.000001%28/02/2026
ISCViShares Morningstar Small-Cap Value ETF<0.000001%28/02/2026
ISMDInspire Small/Mid Cap ETF<0.000001%01/10/2025
JSTCAdasina Social Justice All Cp Glbl ETF<0.000001%27/02/2026
  1    2   3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.